Human Longevity, Inc. (HLI) was founded with a singular, ambitious belief: that aging does not have to be a passive decline but a measurable, manageable, and optimizable process. Built at the intersection of genomics, AI-driven analytics, and advanced clinical care, HLI aims to transform how individuals understand their own biology and how they make decisions that influence long-term well-being.
The company positions itself as a leader in precision health, with a mission anchored not merely in extending lifespan, but in maximizing healthspan — the number of years a person lives in good health, free from chronic disease.
From its earliest days, HLI set out to rethink healthcare from the ground up. Instead of a system that reacts when symptoms appear, the company promotes a model in which deep, continuous assessment helps individuals stay ahead of disease risk. This preventive, data-rich approach is the core of Human Longevity’s identity.
The Health Nucleus: A New Standard in Precision Diagnostics
At the heart of HLI’s offering is the Health Nucleus, an advanced clinical program designed to capture the most complete picture of human health. The Health Nucleus experience brings together whole-genome sequencing, advanced imaging, blood biomarkers, cardiovascular assessments, and metabolic profiling — creating what HLI describes as an unparalleled 360-degree health evaluation.
Whole-genome sequencing forms one of the program’s foundational pillars. By decoding an individual’s complete genetic map, the team at HLI aims to uncover predispositions and potential risk markers long before symptoms appear. Complementing genomic data is a suite of cutting-edge imaging technologies, including full-body MRI scans that can reveal silent abnormalities in the brain, heart, vasculature, and organs. Many clients report that the imaging component alone has identified issues that might otherwise have remained hidden until they were far more difficult to treat.
This integrative diagnostic ecosystem is not a one-off checkup. HLI’s model relies on assembling a detailed, evolving portfolio of personal health data. The company’s clinicians and scientists then interpret this portfolio with the help of AI-driven tools that compare an individual’s results with vast datasets. This comparative analysis is a key differentiator for HLI, as it allows for more precise risk prediction and early detection.
The 100+ Longevity Care Program: A Commitment to Long-Term Wellness
Beyond the initial assessment, HLI offers its signature 100+ Longevity Care Program, designed for individuals who want a sustained, personalized strategy for long-term health. This membership model integrates regular follow-up screenings, annual genomic updates, ongoing clinical guidance, and continuous monitoring of biomarkers that correlate with aging and disease.
The goal is simple but profound: help clients not only detect problems early but actively maintain their biological youthfulness for as long as possible. The company emphasizes that longevity is not merely a function of time, but of choices — guided by the right insights, provided at the right moment.
Participants often describe the program as a blend of high-touch personalized medicine and high-resolution scientific evaluation. By pairing clinicians with data scientists and genomic analysts, HLI turns a client’s biological profile into a living roadmap for preventing disease, improving lifestyle, and delaying age-related decline.
A Data-Driven Approach to Transforming Healthcare
Human Longevity’s model represents a shift toward a more predictive and personalized medical future. Traditional healthcare relies heavily on symptoms to signal disease; HLI’s philosophy turns that idea around. By collecting enormous volumes of biological and clinical data before disease appears, the company believes it can give individuals the time and clarity needed to make informed health decisions.
The vast datasets that HLI has built over the years — representing genomics, imaging, and clinical metrics from thousands of individuals — serve as a scientific backbone that few organizations can match. This data-driven approach not only enhances individual care but also contributes to broader scientific insights into aging, chronic disease risk, and longevity.
The company often highlights how early detection has changed lives: identifying metabolic disorders in their earliest phases, catching developing cardiovascular issues before they progress, and detecting small tumors that may otherwise remain unseen until later stages. For many clients, the power of HLI’s approach lies in its ability to uncover the invisible.
Redefining What It Means to Take Control of Health
Human Longevity, Inc. is reshaping expectations about what healthcare can deliver. Rather than episodic interactions with the medical system, the company advocates for a lifelong partnership between individuals and their clinicians. This partnership is guided by data but grounded in personalized care — a model that blends the precision of modern technology with the human touch of expert clinical judgment.
At a cultural level, HLI represents a new mindset: that people do not need to wait for illness to act, and that aging can be mapped with the same rigor as any scientific process. For entrepreneurs, executives, athletes, and health-conscious individuals seeking a proactive, cutting-edge approach to wellness, the company stands as a pioneer in the longevity space.
A Future Focused on Human Potential
As longevity science advances, HLI is positioned at the forefront of a rapidly evolving field. Its commitment to merging genomics, advanced diagnostics, AI, and preventive medicine reflects a belief that human potential is far greater than current healthcare models acknowledge. Human Longevity, Inc. continues to push toward a future where living past 100 is not just a possibility — but a healthy, vibrant reality.
Wei-Wu He: A Pioneer at the Intersection of Genomics, Innovation, and Longevity
Dr. Wei-Wu He is a scientist, inventor, entrepreneur, and venture capitalist with more than 92 academic papers and over 32 patents. He serves as Executive Chairman of Human Longevity, Inc., sits on the board of OriGene Technologies, and is the founder and General Partner of Emerging Technologies.
Throughout his career, he has been associated with leading institutions such as Human Genome Sciences, IDG-Accel, Massachusetts General Hospital, Intradigm Corp, MithraGen Inc, and the Mayo Clinic, while supporting more than 60 biotech startups. His research spans proteins, antibodies, enzymes, polypeptides, and DNA/RNA encoding, all driven by a central mission to combat human aging and tackle age-related diseases including Alzheimer’s, Parkinson’s, rheumatoid arthritis, traumatic brain injury, and tissue repair challenges.
“We’re grounded in data-driven precision medicine, designed to uncover your health risks early.”
